• Doina PiciuEmail author


This chapter contains brief description of physical characteristics of the most important radioisotopes used in endocrinology: type of decays, energies, half-lives, critical organs, and selective internal dosimetry. Also, in this chapter are presented some examples of dose calculation of most frequent used radioisotopes in endocrinology.


Thyroid Carcinoma Thyroid Gland Critical Organ Exposure Route Internal Exposure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Gelfand MJ, Treves ST, Parisi MT (2009) Survey of radiopharmaceutical administered activities used for tumour and whole body imaging in children. Pediatr Radiol 39(suppl 2):S281–S282Google Scholar
  2. ICRP (1996) Radiological protection and safety in medicine. ICRP publication 73. Ann ICRP 26(2)Google Scholar
  3. ICRP (2000) Prevention of accidental exposures to patients undergoing radiation therapy. ICRP publication 86. Ann ICRP 30(3)Google Scholar
  4. ICRP (2004) Release of patients after therapy with unsealed radionuclides. ICRP publication 94. Ann ICRP 34(2)Google Scholar
  5. ICRP (2007a) The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 37(2–4)Google Scholar
  6. ICRP (2007b) Radiological protection in medicine. ICRP publication 105. Ann ICRP 37(6)Google Scholar
  7. ICRP (2008a) Nuclear decay data for dosimetric calculations. ICRP publication 107. Ann ICRP 38(3)Google Scholar
  8. ICRP (2008b) Radiation dose to patients from radiopharmaceuticals – addendum 3 to ICRP publication 53. ICRP publication 106. Ann ICRP 38(1–2)Google Scholar
  9. ICRP (2009) Education and training in radiological protection for diagnostic and interventional procedures. ICRP publication 113. Ann ICRP 39(5)Google Scholar
  10. Krenning EP, Kwekkenboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with In −111-DTPA –D-Phe1-and[I-123-tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731PubMedCrossRefGoogle Scholar
  11. Lassmann M, Biassoni L, Monsieurs M et al (2007) The new EANM pediatric dosage card. Eur J Nucl Med Mol Imaging 34:796–798, Additional notes and erratum found in Eur J Nucl Med Mol Imaging (2008) 35:1666–1668 and Eur J Nucl Med Mol Imaging 35:2141PubMedCrossRefGoogle Scholar
  12. Treves ST, Davis RT, Fahey FH (2008) Administered radiopharmaceutical doses in children; a survey of 13 pediatric hospitals in North America. J Nucl Med 49:1024–1027PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Nuclear Medicine and Endocrine TumorsInstitute of Oncology Prof. Dr. Ion ChiricuţăCluj-NapocaRomania

Personalised recommendations